Naturhouse Health (FRA:2NH) Research & Development: €0.00 Mil (TTM As of Dec. 2025)


FRA:2NH Naturhouse Health SA FRA:2NH
71 GF Score
Price €2.51
GF Value €1.62
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Naturhouse Health Research & Development?

Naturhouse Health FRA:2NH -0.40% 71 Research & Development is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:2NH with a GF Score™ of 71/100 and a GF Value™ of €1.62 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Naturhouse Health's Research & Development for the six months ended in Dec. 2025 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.

Naturhouse Health  (FRA:2NH) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Naturhouse Health Research & Development Related Terms

Naturhouse Health Research & Development Historical Data

* Premium members only.

The historical data trend for Naturhouse Health's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Naturhouse Health Research & Development Chart

Naturhouse Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Naturhouse Health Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:2NH
71GF Score
Naturhouse Health SA FRA:2NH
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Naturhouse Health Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.00 Mil mean?
Naturhouse Health (FRA:2NH) has a Research & Development of €0.00 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Naturhouse Health and its competitors.
Is Naturhouse Health's Research & Development too high?
Naturhouse Health's current Research & Development is €0.00 Mil. Overall, Naturhouse Health has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Naturhouse Health's Research & Development compare to KHC and GIS?
Naturhouse Health's Research & Development of €0.00 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Consumer Packaged Goods company?
A good Research & Development depends on the Consumer Packaged Goods industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Naturhouse Health and its competitors. Naturhouse Health's current Research & Development is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Naturhouse Health stock overvalued right now?
Based on GuruFocus' analysis, Naturhouse Health (FRA:2NH) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.62, compared to a current price of €2.51 — trading 54.9% above its estimated fair value. The current Research & Development is €0.00 Mil. Naturhouse Health's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Naturhouse Health (FRA:2NH), the current Research & Development is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Naturhouse Health (FRA:2NH) Overvalued in 2026?

Based on GuruFocus' analysis, Naturhouse Health stock appears to be overvalued. The current stock price of €2.51 is trading 54.9% above its estimated GF Value™ of €1.62. GuruFocus considers Naturhouse Health to be Significantly Overvalued.

Key valuation signals for FRA:2NH:

  • Research & Development: €0.00 Mil
  • GF Value™: €1.62 vs. price of €2.51 (54.9% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the FRA:2NH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Naturhouse Health Business Description

Other Exchanges 0R9G:UKNTH:Spain
Address Calle Claudio Coello, 91, 4º Planta, Madrid, ESP, 28006
Naturhouse Health SA provides nutrition & weight management products. The activity of the company is the export, wholesale, and retail sales of all kinds of products related to dietetics, herbal remedies, and natural cosmetics, as well as the preparation, promotion, creation, edition, dissemination, sale, and distribution of all kinds of magazines, books, and brochures and the marketing of dietary products, herbal remedies, and natural cosmetics. This activity is mainly carried out through franchisees and its stores. The geographical segments of the company are Spain, France, Italy, Poland, and Other countries.
71GF Score

Get the complete analysis for FRA:2NH

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.51
Price
€1.62
GF Value